SNWV SANUWAVE Health, Inc.
USHealthcareAs of 2026-07-10 13:24
Why SNWV matters now
SANUWAVE Health, Inc. (SNWV) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.27 with -6.86% on the session and $96.9M in market capitalization; recent performance reads 1-month -44.82% and YTD -69.14%.
The latest financial table shown here is Q1 2026, with revenue of $9.6M, net income of $-1.4M, and EPS of $-0.17. Investors can compare that operating picture with valuation signals such as P/E 12.04 and FCF yield 7.4%.
The latest indexable market news headline is "Sanuwave Health Updates Second Quarter 2026 Guidance" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $54.00; recent insider activity includes Opaleye Management Inc. filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
12.04
PEG
0.09
P/B
43.05
P/S
1.79
EV/EBITDA
4.00
DCF Value
$-35.64
FCF Yield
7.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.7%
Operating Margin
6.4%
Net Margin
36.2%
ROE
-450.6%
ROA
43.3%
ROIC
11.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $9.6M | $-1.4M | $-0.17 |
| Q4 2025 | $13.1M | $6.1M | $0.02 |
| FY 2025 | $44.1M | $11.8M | $0.41 |
| Q3 2025 | $11.5M | $10.3M | $1.13 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$54.00
Target (Median)
$54.00
Target Range
$53.00 - $55.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.34
SANUWAVE Health, Inc. is a company dedicated to the research, development, and commercialization of non-invasive, high-energy acoustic shockwave technology. Operating both domestically and internationally, the firm applies these shockwaves in regenerative medicine and other therapeutic areas. The underlying principle involves stimulating a biological response within the body, prompting self-healing through the restoration and growth of tissues, musculoskeletal structures, and vascular networks. Its flagship regenerative product is the dermaPACE device, specifically engineered for treating diabetic foot ulcers. The company's diverse range of healthcare solutions and pipeline products are designed to trigger vital biologic signaling and angiogenic responses, such as fostering new vascularization and improving microcirculation, ultimately revitalizing the body's natural healing and regenerative capabilities. SANUWAVE also utilizes its proprietary Pulsed Acoustic Cellular Expression (PACE) technology across various medical fields, including wound healing, orthopedics, plastic/cosmetic applications, and cardiac conditions. Beyond its core shockwave offerings, the company provides the UltraMIST device, a non-contact, non-thermal ultrasound therapy for managing conditions like diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. Additionally, its orthoPACE system addresses tendinopathies and both acute and nonunion fractures. Established in 2005, SANUWAVE Health, Inc. is based in Suwanee, Georgia.